Earth Science Tech, Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today provides an update on the progression of its cannabidiol (“CBD”) patents and reacts to the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances.

As previously announced, ETST will soon launch its two CBD-based nutraceutical formulas – a neuron protector and a breast protector – under the provisory patent. In tandem, the Company is developing a new brand for these two formula patents.

ETST further announces that the Quebec Agrifood Innovation Center (“QAIC”) is finishing the standardization of the formulas. By the end of October, TransBiotech will conduct in vitro testing for the formulas’ biological activities, comparing the level of protection provide by ETST’s hemp oil alone versus its hemp oil with other natural ingredients. These components have been meticulously chosen for their bioactivity.

“The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs,” says ETST president and CEO Nickolas Tabraue. “We will provide more details on the progress of these formulas in the near future, as well as an update on the first CBD-based pharmaceutical product we are developing with Bionatus for the treatment of asthma, as announced last year.”

In addition to nutraceutical formulas, ETST’s pipeline also includes CBD-based pharmaceutical formulas. As legalization of cannabis and cannabis-based products continues to spread, ETST expects that its pure hemp oil and new formulas will eventually be sold worldwide. As announced previously, ETST will be a licensed distributor and will work closely with pharmacists and researchers to serve the burgeoning cannabis market.

This expectation is emboldened by the DEA’s recent decision to reclassify FDA-approved drugs that contain cannabis-derived CBD and less than 0.1% tetrahydrocannabinol (THC) as schedule V, the lowest restriction classification. The decision follows the FDA’s first approval of a non-synthetic CBD-based drug to treat rare types of epilepsy.

Once the ruling goes into effect, it could open the door for companies like ETST to develop treatments for other illnesses. The new classification will also render clinical studies with CBD easier to plan.

ETST CEO and Chief Science Officer Dr. Michel Aubé is ecstatic about the changes. “In 2018, we have a much deeper understanding of cannabinoids, cannabinoid-receptors, and the endocannabinoid system than we did decades ago when CBD was classified as a schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.”

ETST plans to share further updates on its CBD patent formulas and CBD-based pharmaceuticals as each progress.

About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to  studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

Earth Science Tech Inc.’s (ETST) CBD Oil is Unique in the Industry

• Earth Science Tech is looking to expand its line of work through two wholly owned subsidiaries
• Its subsidiaries focus on R&D and product development
• The company recently outlined a five-year marketing and manufacturing plan

Earth Science Tech Inc. (OTCQB: ETST) is an aspiring biotech company engaged in the development of cannabinoid-based products and the research and development of medical devices and pharmaceuticals. Using the supercritical CO2 liquid extraction, isolation and micron filtration process, the company manufactures 100 percent natural CBD oil. This pure, easily digested, rich CBD hemp oil is unique to the nutraceuticals industry and represents a significant asset to ETST.

Earth Science Tech is currently looking to expand its operations in the areas of CBD product development and R&D of medical devices and pharmaceuticals through its two wholly owned subsidiaries: Earth Science Pharma Inc. and Cannabis Therapeutics Inc.

Earth Science Pharma Inc. is focused on the research and development of low-cost medical devices and vaccines that benefit women’s health. The company recently introduced its first medical device, MSN-2, a home kit designed for the detection of STIs such as chlamydia. The company has named this kit Hygee. By circumventing the need for laboratory analysis, ETST anticipates that the kit will empower women across the world, giving them a low-cost, noninvasive method to meet their diagnostic health care needs

Aside from Earth Science Pharma’s innovations in the diagnostic health care space, ETST has another subsidiary operating in the burgeoning cannabis industry. Cannabis Therapeutics Inc. is committed to the research and development of medicinal cannabidiol. The company also possesses a provisional application patent for a CBD product that can be used for developing medications to treat breast and ovarian cancers.

ETST recently filed a 10-K annual report with the SEC that included an outline of the company’s five-year expansion plan for manufacturing and marketing its CBD products . The plan includes information about the company’s strategic preparations to scale up the production of its CBD oil, introduce new products and make its innovative hemp products available worldwide

Earth Science Tech has teamed up with the University of Central Oklahoma to conduct research and development projects. In addition, studies from the DV Biologics Laboratory scientifically support and advance the health care benefits of the company’s high-grade hemp CBD oil. These studies show positive results regarding breast cancer and immune cells to support that ETST’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive-result case studies conducted through key health organizations.

“Our CBD-rich hemp oil does not contain any synthetic cannabinoids and is not an isolate,” the SEC report noted. “It contains everything that is naturally occurring in the original industrial hemp plant. With our high-quality, CBD-rich hemp oil you benefit from the natural interaction of phytonutrients in their balanced wide-ranging form that may offer the most benefit for overall wellness.” The report further noted that the company’s “commercialized, CBD-based product line, High-Grade Full Spectrum Cannabinoids, offers seven distinct cannabinoids maximizing all the therapeutic benefits the industrial hemp plant has to offer.”

Through the innovative products offered by its two wholly owned subsidiaries, ETST is well-positioned to stay abreast of current trends in multiple markets.